Harfst & Associates, Inc. Seagen Inc. Transaction History

Harfst & Associates, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 28, 2022	SELL	$108.81 - $179.33 $140,908 - $232,232	-1,295 Reduced 36.15%	2,287 $404,000
Q1 2022 Apr 28, 2022	BUY	$119.61 - $157.85 $75,115 - $99,129	628 Added 21.26%	3,582 $515,000
Q4 2021 Feb 07, 2022	SELL	$142.57 - $190.86 $76,560 - $102,491	-537 Reduced 15.38%	2,954 $456,000
Q3 2021 Oct 28, 2021	BUY	$142.45 - $169.82 $5,698 - $6,792	40 Added 1.16%	3,491 $592,000
Q2 2021 Aug 11, 2021	SELL	$135.08 - $161.1 $52,005 - $62,023	-385 Reduced 10.04%	3,451 $544,000

Q1 2021 May 10, 2021	BUY	$137.51 - $190.8 $527,488 - $731,908	3,836 New	3,836 $532,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Harfst & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Harfst & Associates, Inc. with notifications on news.